NEW YORK--(BUSINESS WIRE)--
(NASDAQ:MDSO), the leading global provider of cloud-based technology and
data analytics for clinical research, today announced its participation
in the 2017
American Society of Clinical Oncology (ASCO) Annual Meeting, the
premier cancer-focused scientific meeting.
Medidata is the first technology company ever selected by ASCO to
present its scientific innovation to advance clinical research and
further drug development in oncology and beyond.
Working with experts from The University of Texas MD Anderson Cancer
Center, Weill Cornell Medical College and long-time customer, Roche,
Medidata will join more than 30,000 oncology professionals in Chicago,
June 2-6, to discuss state-of-the-art treatment modalities, new
therapies and ongoing controversies in the field.
Among a pool of more than 5,700 submissions, ASCO selected both of
Don Berry said: "Synthetic control arms, created out of large pools of
patient data, offer the possibility of early insight during clinical
development programs. Incorporating synthetic control arms directly into
clinical data systems to validate research decisions is an exciting
evolution in the use of historical control data."
Jason Mezey said: "As we learn more about genomes, more opportunities
will present themselves for better, targeted therapies. Linking genomic
data to the extensive data available from clinical research systems is
providing an unprecedented opportunity to discover new insights that
will impact the clinical development process."
David Lee, Medidata's chief data officer, said: "The two acceptances at
ASCO highlight Medidata's ability to help clients generate scientific
findings faster than ever before. These results - based on our SCA and
CTG offerings - are prime examples of the unique value customers realize
from our unmatched data assets and cutting-edge data analytics."
Connect with Medidata
is reinventing global drug and medical device development by creating
the industry's leading cloud-based solutions for clinical research.
Through our advanced applications and intelligent data analytics,
Medidata helps advance the scientific goals of life sciences customers
worldwide, including more than 850 global pharmaceutical companies,
innovative biotech, diagnostic and device firms, leading academic
medical centers, and contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality
and efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled clinical
trial data assets provide deep insights that pave the way for future
growth. The Medidata Clinical Cloud is the primary technology solution
powering clinical trials for 18 of the world's top 25 global
pharmaceutical companies and is used by 18 of the top 25 medical device
developers—from study design and planning through execution, management
View source version on businesswire.com: http://www.businesswire.com/news/home/20170517006376/en/
D'Amico, +1 732-767-4331
Snider, +1 646-362-2997
News Provided by Acquire Media